Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
11
×
europe blog main
11
×
europe top stories
indiana blog main
11
×
indiana top stories
life sciences
national blog main
boston blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
startups
alzheimer's disease
clinical trials
gilead sciences
cancer immunotherapy
deals
eli lilly
merck
novartis
What
bio
roundup
cancer
drug
fda
medicines
acquisitions
amid
approval
bombast
buy
caught
ceo
coronavirus
covid
daniel
days
debate
debut
develop
discussion
efforts
gilead
ipo
meso’s
miss
moves
o’day
pandemic
patients
pfizer’s
presidential
promise
response
sciences
tuesday’s
vaccine
viewers
week
abbvie’s
Language
unset
11
×
Current search:
biotech
×
" europe blog main "
×
unset
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More